Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
View ORCID ProfileSharifa Nasreen, Hannah Chung, Siyi He, Kevin A. Brown, Jonathan B. Gubbay, Sarah A. Buchan, Deshayne B. Fell, Peter C. Austin, Kevin L. Schwartz, Maria E. Sundaram, Andrew Calzavara, Branson Chen, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
doi: https://doi.org/10.1101/2021.06.28.21259420
Sharifa Nasreen
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
PhDHannah Chung
1ICES, Toronto, ON
MPHSiyi He
1ICES, Toronto, ON
MScKevin A. Brown
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
PhDJonathan B. Gubbay
3Public Health Ontario, ON
4Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON
MBBSSarah A. Buchan
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
5Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
PhDDeshayne B. Fell
1ICES, Toronto, ON
6School of Epidemiology and Public Health, University of Ottawa, ON
7Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON
PhDPeter C. Austin
1ICES, Toronto, ON
8Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON
PhDKevin L. Schwartz
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
MDMaria E. Sundaram
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
9Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA
PhDAndrew Calzavara
1ICES, Toronto, ON
MScBranson Chen
1ICES, Toronto, ON
MScMina Tadrous
1ICES, Toronto, ON
10Women’s College Hospital, Toronto, ON
PhDKumanan Wilson
11Department of Medicine, University of Ottawa, Ottawa, ON
12Bruyere and Ottawa Hospital Research Institutes, Ottawa, ON
MDSarah E. Wilson
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
5Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
MDJeffrey C. Kwong
1ICES, Toronto, ON
2Dalla Lana School of Public Health, University of Toronto, Toronto, ON
3Public Health Ontario, ON
5Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON
13Department of Family and Community Medicine, University of Toronto, Toronto, ON
14University Health Network, Toronto, ON
MD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das{at}ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.
Posted September 30, 2021.
Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
Sharifa Nasreen, Hannah Chung, Siyi He, Kevin A. Brown, Jonathan B. Gubbay, Sarah A. Buchan, Deshayne B. Fell, Peter C. Austin, Kevin L. Schwartz, Maria E. Sundaram, Andrew Calzavara, Branson Chen, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong
medRxiv 2021.06.28.21259420; doi: https://doi.org/10.1101/2021.06.28.21259420
Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
Sharifa Nasreen, Hannah Chung, Siyi He, Kevin A. Brown, Jonathan B. Gubbay, Sarah A. Buchan, Deshayne B. Fell, Peter C. Austin, Kevin L. Schwartz, Maria E. Sundaram, Andrew Calzavara, Branson Chen, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong
medRxiv 2021.06.28.21259420; doi: https://doi.org/10.1101/2021.06.28.21259420
Subject Area
Subject Areas
- Addiction Medicine (330)
- Allergy and Immunology (651)
- Anesthesia (174)
- Cardiovascular Medicine (2516)
- Dermatology (210)
- Emergency Medicine (386)
- Epidemiology (11993)
- Forensic Medicine (10)
- Gastroenterology (721)
- Genetic and Genomic Medicine (3913)
- Geriatric Medicine (367)
- Health Economics (654)
- Health Informatics (2528)
- Health Policy (973)
- Hematology (351)
- HIV/AIDS (813)
- Medical Education (387)
- Medical Ethics (106)
- Nephrology (418)
- Neurology (3669)
- Nursing (205)
- Nutrition (548)
- Oncology (1910)
- Ophthalmology (555)
- Orthopedics (230)
- Otolaryngology (299)
- Pain Medicine (243)
- Palliative Medicine (71)
- Pathology (465)
- Pediatrics (1076)
- Primary Care Research (435)
- Public and Global Health (6346)
- Radiology and Imaging (1342)
- Respiratory Medicine (847)
- Rheumatology (389)
- Sports Medicine (334)
- Surgery (426)
- Toxicology (51)
- Transplantation (180)
- Urology (156)